CJC-1295 + Ipamorelin protocol
CJC-1295 (no DAC) + Ipamorelin blend. The published work on this compound is animal or cell-culture research. No human dosing schedule exists to cite.
How CJC-1295 + Ipamorelin works
Pairs a GHRH analog with a ghrelin-receptor agonist. The rationale is that the two act on different receptors, so the combination is expected to produce a larger GH pulse than either alone. Note the CJC here is the no-DAC form, with a half-life of minutes rather than days.
CJC-1295 + Ipamorelin dosing — what the literature actually supports
We publish a schedule when there is a citable human source and we say so when there is not. Filling this space with a number nobody measured would make the page look more complete and be worth less than nothing to you.
Reconstitution and measurement
This part is arithmetic and does not depend on the evidence level. Concentration is vial size divided by the bacteriostatic water you add. Draw volume is your target amount divided by that concentration. Units are draw volume times 100, because a U-100 syringe reads 100 units per millilitre. Common vials for CJC-1295 + Ipamorelin: 10 mg total (5/5).
Storage and stability
Reported effects
- No human safety data for the combination.
- Component-level data exists for each separately; see the CJC-1295 with DAC and Ipamorelin pages, noting the DAC distinction.
Sourcing CJC-1295 + Ipamorelin
Whatever you are working with, the documentation matters more than the price. Ask for a batch certificate of analysis whose lot number matches the vial you actually receive — a COA for a different batch tells you nothing about yours.
CJC-1295/Ipamorelin Blend at Summit Research Supply → Grade a COA first
Summit is the supplier we feature and an affiliate link. Our COA checklist applies the same way to any vendor.
